Although the Food and Drug Administration (FDA) previously approved riluzole and edaravone for all forms of ALS and tofersen for SOD1-positive ALS, additional pharmacotherapies are urgently needed [96]. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.